Viking Therapeutics (VKTX) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Viking Therapeutics (VKTX) Tops Q4 EPS by 4c

Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update

March 7, 2018 4:05 PM EST

SAN DIEGO, March 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on its clinical pipeline and other corporate developments.

Highlights from, and Subsequent to, the Quarter Ended December 31, 2017

"The last year has been transformative for Viking as we announced positive clinical data for our lead program, VK5211 for hip fracture, advanced our Phase 2 clinical trial... More